This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

New Developments in Antipsychotic Therapy.

Peter J. Weiden, M.D.; W. Wolfgang Fleischhacker, M.D.; John M. Kane, M.D.; Stephen R. Marder, M.D.; J. Michael Ryan, M.D.; and Stephen M. Strakowski, M.D.

Published: November 15, 2003

Article Abstract

Click to enlarge page

W. Wolfgang Fleischhacker, M.D., began the meeting by reviewing the history of the mechanism-based development of antipsychotic drugs. Mechanism-based studies commenced with Paul Janssen’s clinical observation in Belgian cyclists that the dopamine agonist amphetamine led to psychosis and abnormal movements similar to those seen in schizophrenia patients. Expanded knowledge about the pathophysiology of schizophrenia, especially the development and acceptance of the dopamine hypothesis, has also motivated more mechanism-based research.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: